Personalized cancer vaccines pass first major clinical test
Elie Dolgin • July 12, 2023
Moderna, BioNTech and others hope that personalized cancer vaccines will soon live up to their potential — even as they work out the wrinkles for the best use of their platform technologies.
Researchers have long suspected that therapeutic vaccines customized to a patient’s cancer might help raise the immune system to fight off the disease. Phase II data from a randomized trial of Moderna’s personalized vaccine mRNA-4157 now provide evidence that these therapeutics can yield meaningful — if still preliminary — clinical benefit.
The findings, reported earlier this year, have revitalized the cancer vaccine community, inspiring companies to intensify efforts to stimulate the immune system to recognize tumour-specific mutations known as neoantigens or neoepitopes.
Continue reading at Nature Reviews Drug Discovery.
A closer listen to lion calls may help map where the big cat is under threat.
Scientists remain split on whether rope-pulling ingenuity counts as tool use.